|
Delayed
NSE India S.E.
09:56:41 11/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 1,845.90 INR | -0.81% |
|
-2.80% | +7.34% |
| 09-09 | Sun Pharma Sets Up Global Treasury Center in India's GIFT City | MT |
| 09-09 | Sun Pharma Assigned Baa1, BBB+ Ratings by Moody's, S&P | MT |
| Market Cap | 4,465B 46.7B 40.16B 37.9B 34.52B 64.54B 65.12B 451B 174B 2,265B 175B 172B 7,194B | P/E 2027 * |
34.3x | P/E 2028 * | 29.1x |
|---|---|---|---|---|---|
| Enterprise Value | 4,194B 43.87B 37.73B 35.6B 32.43B 60.62B 61.18B 424B 163B 2,128B 165B 161B 6,758B | EV / Sales 2027 * |
6.44x | EV / Sales 2028 * | 5.66x |
| Free-Float |
44.39% | Yield 2027 * |
0.92% | Yield 2028 * | 1.07% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript : Sun Pharmaceutical Industries Ltd.
| 1 day | -0.81% | ||
| 1 week | -2.80% | ||
| Current month | -7.00% | ||
| 1 month | -4.95% | ||
| 3 months | +2.88% | ||
| 6 months | +1.10% | ||
| Current year | +7.34% |
| 1 week | 1,839 |  | 1,907.8 |
| 1 month | 1,839 | | 1,984.8 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.81% | -2.80% | +14.67% | +62.36% | 46.7B | |
| -1.40% | -5.99% | +34.59% | +111.44% | 39.11B | |
| +0.48% | +0.28% | +7.62% | +78.68% | 11.66B | |
| -1.51% | -2.32% | -13.33% | +8.45% | 11.6B | |
| 0.00% | +0.38% | +20.28% | +137.27% | 9.19B | |
| -0.72% | -2.50% | +24.28% | +32.94% | 7.27B | |
| -0.12% | -1.04% | +13.35% | +197.40% | 7.13B | |
| -1.30% | -5.53% | +33.47% | -18.87% | 7.15B | |
| -1.43% | -1.37% | -43.32% | +21.01% | 5.13B | |
| -0.97% | +0.61% | +35.54% | +101.68% | 4.6B | |
| Average | -0.77% | -2.62% | +12.72% | +73.24% | 14.95B | |
| Weighted average by Cap. | -0.87% | -3.49% | +17.46% | +77.81% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.81B 5.86B 5.53B 5.03B 9.41B 9.49B 65.8B 25.33B 330B 25.57B 25.01B 1,049B | 729B 7.63B 6.56B 6.19B 5.64B 10.54B 10.63B 73.69B 28.36B 370B 28.63B 28.01B 1,174B |
| Net income | 130B 1.36B 1.17B 1.1B 1B 1.87B 1.89B 13.11B 5.04B 65.77B 5.09B 4.98B 209B | 154B 1.61B 1.38B 1.3B 1.19B 2.22B 2.24B 15.53B 5.98B 77.93B 6.03B 5.9B 248B |
| Net Debt | -271B -2.83B -2.43B -2.3B -2.09B -3.91B -3.95B -27.36B -10.53B -137B -10.63B -10.4B -436B | -338B -3.54B -3.04B -2.87B -2.62B -4.89B -4.94B -34.21B -13.17B -172B -13.29B -13B -545B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/26 | ₹1,845.90 | -0.81% | 374,702 |
| 10/09/26 | ₹1,861.00 | -0.21% | 1,178,648 |
| 09/09/26 | ₹1,864.90 | -1.11% | 1,396,896 |
| 08/09/26 | ₹1,885.90 | -0.48% | 1,422,627 |
| 07/09/26 | ₹1,895.00 | -0.21% | 1,579,345 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
